Clinical Trial Update: A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluated dolutegravir (GSK1349572) in HIV-infected individuals with resistance to raltegravir; the trial has completed and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 2 | Status: COMPLETED | Results posted: 2013-10-21